期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 12, 期 529, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aay1809
关键词
-
资金
- NIH [R37AG027924, RF1AG057181, R01AG035355, RF1AG046205, RF1AG051504, P01NS074969]
- Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic
- Lewy Body Dementia Center Without Walls [U54NS110435]
The apolipoprotein E (APOE)epsilon 4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease mainly by driving amyloid-beta pathology. Recently, APOE4 has also been found to be a genetic risk factor for Lewy body dementia (LBD), which includes dementia with Lewy bodies and Parkinson's disease dementia. How APOE4 drives risk of LBD and whether it has a direct effect on alpha-synuclein pathology are not clear. Here, we generated a mouse model of synucleinopathy using an adeno-associated virus gene delivery of alpha-synuclein in human APOE-targeted replacement mice expressing APOE2, APOE3, or APOE4. We found that APOE4, but not APOE2 or APOE3, increased alpha-synuclein pathology, impaired behavioral performances, worsened neuronal and synaptic loss, and increased astrogliosis at 9 months of age. Transcriptomic profiling in APOE4-expressing alpha-synuclein mice highlighted altered lipid and energy metabolism and synapse-related pathways. We also observed an effect of APOE4 on alpha-synuclein pathology in human postmortem brains with LBD and minimal amyloid pathology. Our data demonstrate a pathogenic role of APOE4 in exacerbating alpha-synuclein pathology independent of amyloid, providing mechanistic insights into how APOE4 increases the risk of LBD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据